07.07.2022 • News

Thyssenkrupp Nucera Wins India Caustic Soda Project

German technology company Thyssenkrupp Nucera has won a contract to expand a caustic soda plant for India’s Kutch Chemical Industries. The contract’s value is in the low double-digit million-euro range.

Thyssenkrupp Nucera will grant a license and supply proprietary equipment to expand the plant, which is located in Padana, Gujarat, and comprises five electrolyzers that are based on the German firm’s bipolar membrane single element technology.

The project – Thyssenkrupp Nucera’s second for Kutch – will more than double current capacity, providing an additional 670 t/d. Completion and commissioning are scheduled for some time in 2023.

Kutch said the project will strengthen its market position and meet growing regional demand for basic chemicals, as well as its own rising demand. Caustic soda is used in a large number of end-products such as detergents, soaps and disinfectants, as well as processing raw aluminum.

Part of the Goyal Group of Industries, Kutch produces specialty chemicals that include intermediates for pharmaceuticals, agrochemicals and dyes, and the company touts itself as being “highly experienced” in chlorination, nitration, sulfonation, hydrogenation, ethoxylation and ammonolysis processes.

Author: Elaine Burridge, Freelance Journalist

© Thyssenkrupp Nucera
© Thyssenkrupp Nucera

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read